Remove Drug Delivery Remove Life Science Remove Packaging
article thumbnail

PCI Pharma Services Invests Over $365 Million in EU, US Facilities to Drive Clinical and Commercial Supply of Advanced Drug Delivery and Drug Device Combination Products

XTalks

Highlights include expansion of biotech operations in Philadelphia, acquisition of a new pharma-device facility near Dublin, Ireland, and a new Center of Excellence for advanced drug delivery and drug-device combination product assembly in Rockford, Illinois.

article thumbnail

Employee Retention and Motivation Strategies for Life Science Companies — Free Onboarding Checklist Included

XTalks

Employee retention and motivation is a challenge that all life science companies face. Life science companies often have to follow a complex regulatory framework that is associated with high risks, which is why maintaining corporate compliance is essential. Training and Development Opportunities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Meeting global demand for patient independence: SHL Medical expands production in Charleston, US

Pharmaceutical Technology

SHL Medical is a world-leading solutions provider for advanced drug delivery systems with a unified purpose to further enable patient independence. As it establishes these new operations, SHL Medical will be welcomed into a growing community of life sciences companies expanding in and around Charleston.

article thumbnail

FDA Warns of Dosing Errors with Compounded Semaglutide Injectables

XTalks

These issues primarily stem from patients and healthcare providers miscalculating or incorrectly administering the drug. Compounded semaglutide products, unlike the US Food and Drug Administration (FDA)-approved ones, can vary widely in strength and packaging, making it easy for mistakes to happen.

article thumbnail

FTC Report Finds Top PBMs Raked in $7.3B from Specialty Drug Markups

XTalks

PBMs serve as intermediaries between insurers, pharmacies and drug manufacturers, negotiating discounts and managing drug formularies. While PBMs were originally intended to lower costs and streamline drug delivery, critics argue that their practices often lead to inflated prices and restricted access for consumers.

Drugs 59
article thumbnail

Subcutaneous Biologics Market Analysis: Current Trends and Future Outlook

Roots Analysis

In order to help circumvent these disadvantages, several drug delivery devices, which enable patients to self-administer drugs through subcutaneous route are now being developed. She holds a bachelors degree in Pharmaceutical Sciences which has provided her with a solid foundation in the ever-growing domain of life-sciences.